Each year, the Academy of Managed Care Pharmacy (AMCP) holds a Pharmacy & Therapeutics (P&T) Competition for student pharmacists. In practice, P&T committees decide which medications will be on the institution or insurance company’s formulary. A formulary is a list of drugs that prescribers can use, or what insurance will cover. The committee is comprised of many different health care professionals, including a pharmacist. Together, they weigh the cost and evidence-based efficacy of each medication. The P&T competition begins when AMCP reveals the drug they have chosen for the year. Typically, it is a recently FDA approved medication. They then provide a dossier containing important drug information and clinical trial results. Each college of pharmacy is allowed to submit one monograph to the national competition. Teams are comprised of up to four people. They must write a drug monograph and create a PowerPoint presentation. The monograph includes clinical and economic evidence, safety and efficacy, coverage criteria, as well as a background and pathophysiology on the disease states the drug treats. Other treatment options are also analyzed. The team then recommends whether or not the drug should be added to the formulary, and which tier it should be on. This year, the drug was Dupixent®, for the maintenance of moderate-to-severe asthma in people aged 12 or older.
Stuart, K., Miller, A., Koebel, K., and Kier, K. (2020, April). The Proposed Formulary Status and Evidence-based Use of Dupilumab (Dupixent®) for the FDA Approved Treatment of Asthma [Presentation]. AMCP 2020 Annual Meeting, Houston, TX. https://digitalcommons.onu.edu/honors_student/1